menu
    • menu
    [{"orgOrder":0,"company":"Teijin Pharma","sponsor":"TransThera Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Teijin Pharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Teijin Pharma \/ TransThera Biosciences","highestDevelopmentStatusID":"2","companyTruncated":"Teijin Pharma \/ TransThera Biosciences"},{"orgOrder":0,"company":"Teijin Pharma","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2021","type":"Divestment","leadProduct":"Alogliptin Benzoate","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Teijin Pharma","amount2":1.25,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":1.25,"dosageForm":"Tablet","sponsorNew":"Teijin Pharma \/ Teijin Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Teijin Pharma \/ Teijin Pharma"},{"orgOrder":0,"company":"Teijin Pharma","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2021","type":"Divestment","leadProduct":"Alogliptin Benzoate","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Teijin Pharma","amount2":1.25,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":1.25,"dosageForm":"Tablet","sponsorNew":"Teijin Pharma \/ Teijin Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Teijin Pharma \/ Teijin Pharma"},{"orgOrder":0,"company":"Teijin Pharma","sponsor":"Merz Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"IncobotulinumtoxinA","moa":"Ach","graph1":"Neurology","graph2":"Approved","graph3":"Teijin Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Teijin Pharma \/ Merz Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Teijin Pharma \/ Merz Therapeutics"},{"orgOrder":0,"company":"Teijin Pharma","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Nephrology","graph2":"Preclinical","graph3":"Teijin Pharma","amount2":0.23000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0.23000000000000001,"dosageForm":"","sponsorNew":"Teijin Pharma \/ Novartis","highestDevelopmentStatusID":"4","companyTruncated":"Teijin Pharma \/ Novartis"},{"orgOrder":0,"company":"Teijin Pharma","sponsor":"Ascendis Pharma","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Lonapegsomatropin","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Teijin Pharma","amount2":0.25,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0.25,"dosageForm":"Injection","sponsorNew":"Teijin Pharma \/ Teijin Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Teijin Pharma \/ Teijin Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Teijin Pharma

    Menu

    Teijin Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Teijin Pharma

                            Japan arrow
                            2024 ACI Convention
                            Not Confirmed

                            Teijin Pharma

                            Japan arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lonapegsomatropin

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase III

                            Recipient : Ascendis Pharma

                            Deal Size : $245.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Ascendis Pharma Announces Strategic Partnership with Teijin Limited in Japan

                            Details : Under the agreement, Teijin will receive exclusive license to further develop and commercialize TransCon hGH (lonapegsomatropin-tcgd), TransCon PTH, and TransCon CNP for endocrinology rare disease, in Japan.

                            Brand Name : TransCon hGH

                            Molecule Type : Large molecule

                            Upfront Cash : $70.0 million

                            November 29, 2023

                            Lead Product(s) : Lonapegsomatropin

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase III

                            Recipient : Ascendis Pharma

                            Deal Size : $245.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Teijin Pharma

                            Japan arrow
                            2024 ACI Convention
                            Not Confirmed

                            Teijin Pharma

                            Japan arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Nephrology

                            Study Phase : Preclinical

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : $230.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Teijin Pharma Grants Global Exclusive License for Investigational Small Molecule Candidate in Kidney Disease

                            Details : Teijin will grant Novartis exclusive worldwide rights to research, develop, manufacture and commercialize an investigational small molecule candidate for proteinuric kidney diseases. The candidate is believed to impact the pathogenesis of multiple kidney...

                            Brand Name : Undislcosed

                            Molecule Type : Small molecule

                            Upfront Cash : $30.0 million

                            March 06, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Nephrology

                            Highest Development Status : Preclinical

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : $230.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Teijin Pharma

                            Japan arrow
                            2024 ACI Convention
                            Not Confirmed

                            Teijin Pharma

                            Japan arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IncobotulinumtoxinA

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Merz Pharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Teijin Receives Additional Approval in Japan for Botulinum Toxin Type A Xeomin ® From Merz

                            Details : Xeomin ® is effective in the treatment of peripheral cholinergic nerve endings by decreasing the contraction of voluntary muscles, and relieves muscle tone by inhibiting the release of a neurotransmitter, acetylcholine.

                            Brand Name : Xeomin

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 23, 2021

                            Lead Product(s) : IncobotulinumtoxinA

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Merz Pharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Teijin Pharma

                            Japan arrow
                            2024 ACI Convention
                            Not Confirmed

                            Teijin Pharma

                            Japan arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Alogliptin Benzoate,Pioglitazone

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved

                            Recipient : Takeda Pharmaceutical

                            Deal Size : $1,250.0 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Takeda Completes Sale of Four Diabetes Products in Japan to Teijin Pharma Limited

                            Details : The portfolio divested to Teijin Pharma was comprised of four non-core type 2 diabetes products (Nesina®, Liovel®, Inisync® and Zafatek®) sold in Japan, which generated total sales of approximately JPY 30.8 billion in FY2019.

                            Brand Name : Liovel

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 01, 2021

                            Lead Product(s) : Alogliptin Benzoate,Pioglitazone

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved

                            Recipient : Takeda Pharmaceutical

                            Deal Size : $1,250.0 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Teijin Pharma

                            Japan arrow
                            2024 ACI Convention
                            Not Confirmed

                            Teijin Pharma

                            Japan arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Alogliptin Benzoate

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved

                            Recipient : Takeda Pharmaceutical

                            Deal Size : $1,250.0 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Takeda to Divest Four Diabetes Products in Japan to Teijin Pharma Limited

                            Details : The portfolio to be divested to Teijin Pharma is comprised of four non-core type 2 diabetes products (Nesina®, Liovel®, Inisync® and Zafatek®) sold in Japan, which generated total sales of approximately JPY 30.8 billion in FY2019.

                            Brand Name : Nesina

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 26, 2021

                            Lead Product(s) : Alogliptin Benzoate

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved

                            Recipient : Takeda Pharmaceutical

                            Deal Size : $1,250.0 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Teijin Pharma

                            Japan arrow
                            2024 ACI Convention
                            Not Confirmed

                            Teijin Pharma

                            Japan arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : TransThera Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Teijin Pharma and TransThera Biosciences Form Strategic R&D Collaboration

                            Details : Teijin Pharma and TransThera will establish a joint drug discovery collaboration of multiple drug targets with the immediate goal of acquiring compounds as candidates for new drug development based on the targets and compounds found by Teijin Pharma.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 18, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : TransThera Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth